Glaukos Corporation is a medical technology company dedicated to the development and commercialization of innovative products for the treatment of glaucoma, corneal disorders, and retinal diseases. It... Glaukos Corporation is a medical technology company dedicated to the development and commercialization of innovative products for the treatment of glaucoma, corneal disorders, and retinal diseases. Its primary function is to address the substantial unmet medical needs present in ophthalmic healthcare. Glaukos is particularly recognized for pioneering novel micro-invasive glaucoma surgery (MIGS) devices, which are designed to reduce intraocular pressure in glaucoma patients through minimally invasive techniques. The company's product portfolio includes various implantable devices and surgical systems, offering alternatives to traditional invasive surgery and medication. Glaukos Corporation significantly impacts the healthcare industry, especially the ophthalmology sector, by providing solutions that improve patient outcomes and quality of life. Its innovations are crucial in the market, as glaucoma remains one of the leading causes of irreversible blindness globally. By focusing on clinically proven products and expanding its technological reach, Glaukos plays a transformative role in enhancing therapeutic standards and contributing to greater accessibility of advanced eye care treatments.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

Glaukos is not subject to EU Taxonomy reporting

Based on current regulatory requirements, Glaukos is not required to report EU Taxonomy data under the CSRD framework. As a result, we have not conducted a detailed EU Taxonomy data review for this company.

If you believe this assessment should be revisited, you may submit a data coverage request and our team will review the company's regulatory applicability.

Would you like us to review Glaukos's data?

Create a free Tracenable account to signal interest in having our team review data for Glaukos.

Legal Center Contact Us